# SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke

> **NCT07105917** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 1050 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** SGLT-2 inhibitors
- **OTHER:** Standard medical treatment

## Key facts

- **NCT ID:** NCT07105917
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 1050 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07105917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07105917, "SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT07105917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*